No abstract available.
Hemorrhage ; Ticlopidine

No abstract available.
Diabetes Mellitus ; Stents ; Ticlopidine

No abstract available.
Jaundice, Obstructive* ; Pancytopenia* ; Ticlopidine*

No abstract available.
Bupropion ; Sexual Behavior ; Ticlopidine

The aim of this update of Korean clinical practice guidelines for stroke is to provide timely evidence-based recommendations on the antiplatelet therapy in secondary prevention of stroke. Evidence-based recommendations are included for the use of antiplatelet agents for noncardioembolic stroke. Changes in the guidelines necessitated by new evidence will be continuously reflected in the new guideline.
Aspirin ; Platelet Aggregation Inhibitors ; Secondary Prevention ; Stroke ; Ticlopidine

BACKGROUND AND OBJECTIVES: Cilostazol is a potent antiplatelet agent with antiproliferative properties. Few data are available about the effect of cilostazol on post-stenting restenosis. The aim of this study was to evaluate the impact of cilostazol on post-stenting restenosis. MATERIALS AND METHOD: Four hundred and nine patients (494 lesions) scheduled for elective stenting were randomized to receive aspirin plus ticlopidine (group A, n=01, 240 lesions) or aspirin plus cilostazol (group B, n=08, 254 lesions), starting 2 days before stenting. Ticlopidine was given for 1 month and cilostazol for 6 months. Follow-up angiography was performed at 6 months, and clinical evaluation at regular intervals. RESULTS: Baseline characteristics were similar between the two groups. Procedural success rate was 99.6% in group A and 100% in group B. There were no cases of stent thrombosis after stenting. Angiographic follow-up was performed in 380 of the 494 eligible lesions and angiographic restenosis rate was 27% in group A, and 22.9% in group B (p=S). However, diffuse type in-stent restenosis was more common in group A than in group B (54.2% vs 26.8%, respectively, p<0.05). In diabetic patients, angiographic restenosis rate was 50% in group A and 21.7% in group B (p<0.05). Clinical events during the follow-up did not differ between the two groups. CONCLUSION: The combination therapy with aspirin plus cilostazol seems to be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine, but it does not reduce the overall angiographic restenosis rate after elective coronary stenting.
Angiography ; Aspirin ; Follow-Up Studies ; Humans ; Stents* ; Thrombosis ; Ticlopidine

The antiplatelet aggregation effect of ticlopidine was studied in 22 cases of coronary artery disease(CAD) and 17 cases of control by obseving changes of plarma beta-thromboglobulin(beta-TG) and platelet factor 4(PF-4) before and after administration of ticlopidine 500mmg daily for 2 weeks. 1) Compared with the controls, CAD patients had significantly greater plasm levels of beta-TG(52.6+/-32.7ng/ml. mean +/-SD vs. 91.0+/-52.0, P<0.05) and PF-4(17.5+/-12.8 ng/ml vs. 32.9+/-24.5, P<0.05). 2) In controls, plasma levels of beta-TG and PF-4 didn't change significantly after taking ticlopidine. 3) In CAD patients, plasma levels of beta-TG (91.0+/-52.0ng/ml vs. 53.9+/-20.0, P<0.05) and PF-4(32.9+/-24.5ng/ml vs. 18.8 +/-11.9(P<0.05) decreased significantly after ticlopidine. 4) The side effects were observed in 2 cases such as mild indigestion and urticaria.
Blood Platelets ; Coronary Vessels ; Dyspepsia ; Humans ; Plasma ; Ticlopidine* ; Urticaria

Genetic Variation ; Humans ; Ticlopidine ; analogs & derivatives ; pharmacokinetics ; pharmacology

Drug Resistance ; Drug-Eluting Stents ; Humans ; Ticlopidine ; analogs & derivatives ; pharmacology

Ticlopidine hydrochloride is world-wide used antiplatelet agent that inhibit ADP pathway. Its clinical side effects are the change of the blood picture, allergic skin reaction and gastrointestinal symptoms. We report three patients with severe cholestatic hepatitis caused by ticlopidine. They developed jaundice about 20days after taking ticlopidine (500 mg/day). Infectious and immunological etiologies were excluded by serology. There was no history of alcohol or drug abuse. Their symptoms were gradually subsided for a few months after discontinuing ticlopidine.
Adenosine Diphosphate ; Hepatitis* ; Humans ; Jaundice ; Skin ; Substance-Related Disorders ; Ticlopidine